secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2025-05-23T23:59:59+00:00
Accession:  0001140361-25-020353
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics raises $20M in public offering for Phase 2 F351 trial
-----------------------------------------------------------------------

- Issued 2,222,222 shares at $9.00/share; underwriters have 30-day option for 333,333 additional shares.
- Net proceeds estimated at $18.5M after discounts and expenses.
- Funds U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis, R&D, and working capital.
- Offering expected to close May 27, 2025; Jefferies LLC is sole book-running manager.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036125020353/0001140361-25-020353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036125020353/ef20049643_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-020353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer